DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

MARCH 26, 2025

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 Bozkurt A, et al.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.

Kidney Disease 49

Kidney Disease Heart Failure Preserved Ejection Fraction Blood Pressure 49

Circulation: Heart Failure

NOVEMBER 25, 2024

Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction. The use of MRAs has been limited due to excessive concern about hyperkalemia.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

Open Heart

APRIL 24, 2024

HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). and 29.2%, p<0.001).

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52